WRN-IN-26

Overview

WRN-IN-26 is an orally active Werner syndrome helicase (WRN) inhibitor with a human K i value of 58.7 μM and an IC 50 value of 0.026 μM. WRN-IN-26 selectively targets the cysteine residues of WRN. WRN-IN-26 induces the expression of p21 protein in MSI-H tumor cells. WRN-IN-26 inhibits the growth of MSI-H tumor cells and exhibits potent in vivo efficacy in MSI-H xenograft tumor models. WRN-IN-26 can be used for the research of microsatellite instability-high (MSI-H) cancers.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > PAK

Product Information

• Catalog No.: HY-183610
• CAS No.: 3059172-54-9
• Molecular Formula: C28H27F3N2O5S
• Molecular Weight: 560.58
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source